RGDXQ.US Response Genetics Inc
- Market cap
- USD 1.37K
- P/E
- -
- P/B
- 0.00x
- ROE
- -61.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2015.
Is RGDXQ.US undervalued?
Graham numberThe Graham number of Response Genetics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Response Genetics Inc fundamental analysis
No fundamental analysis for Response Genetics Inc yet.
Response Genetics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Response Genetics Inc
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma thro…
Full company profileResponse Genetics Inc financial statements
Response Genetics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.02M | 7.79M | 7.12M | 9.07M | 21.3M | 22.6M | 18.7M | 19.8M | 16.7M | 18.0M |
| Gross Profit | 3.56M | 3.74M | 3.53M | 3.35M | 10.8M | 10.9M | 8.32M | 9.35M | 6.71M | 3.94M |
| Operating Income | -1.63M | -5.50M | -9.86M | -9.41M | -4.88M | -5.68M | -7.66M | -7.95M | -13.0M | -21.4M |
| EBITDA | -1.32M | -4.93M | -8.71M | -8.95M | -4.19M | -5.32M | -7.20M | -10.0M | -12.2M | -19.4M |
| Net Income | -1.36M | -5.05M | -9.49M | -9.34M | -4.67M | -5.72M | -7.37M | -7.48M | -13.5M | -20.2M |
| EPS | -0.50 | -0.72 | -0.93 | -0.70 | -0.26 | -0.30 | -0.28 | -0.22 | -0.35 | -0.52 |
| Balance Sheet | ||||||||||
| Total Assets | 8.26M | 24.4M | 13.5M | 10.8M | 10.6M | 7.85M | 16.6M | 18.1M | 13.4M | 48.9M |
| Total Liabilities | 13.8M | 9.31M | 6.68M | 10.1M | 13.9M | 14.0M | 17.1M | 12.3M | 14.6M | 15.9M |
| Shareholders' Equity | -5.50M | 15.1M | 6.87M | 649K | -3.28M | -6.14M | -542K | 5.76M | -1.17M | 33.0M |
| Cash & Short-term Investments | 4.93M | 17.0M | 9.55M | 7.06M | 4.12M | 1.70M | 9.04M | 8.15M | 2.22M | 19.5M |
| Total Debt | 717K | - | - | - | - | 1.39M | 1.24M | 1.29M | 9.67M | 6.37M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.18M | -3.49M | -6.79M | -8.41M | -6.49M | -5.08M | -8.01M | -6.49M | -14.3M | -13.6M |
| Capital Expenditure | 913K | 1.98M | 577K | 224K | 392K | 391K | 957K | 608K | 104K | 1.15M |
| Free Cash Flow | 2.26M | -5.47M | -7.37M | -8.64M | -6.88M | -5.48M | -8.97M | -7.10M | -14.4M | -14.7M |
| Ratios | ||||||||||
| ROE | - | -33.5% | -138.1% | -1,438.8% | - | - | - | -129.9% | - | -61.1% |
| ROA | -16.4% | -20.7% | -70.0% | -86.5% | -44.1% | -72.9% | -44.4% | -41.4% | -100.7% | -41.3% |
| Net Profit Margin | -22.6% | -64.9% | -133.1% | -103.0% | -21.9% | -25.3% | -39.3% | -37.8% | -81.0% | -111.9% |
| Debt to Equity | - | - | - | - | - | - | - | 0.22x | - | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Response Genetics Inc dividends
Response Genetics Inc has not paid dividends in the last 10 fiscal years.
Who owns Response Genetics Inc
Ownership data of Response Genetics Inc is not available yet.
Response Genetics Inc company profile
- Company name
- Response Genetics Inc
- Ticker
- RGDXQ.US
- Exchange
- USA Stocks
- Listed since
- Jun 5, 2007
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 96
- Fiscal year end
- December
- Address
- 1640 Marengo Street, Los Angeles, CA, United States, 90033
- Phone
- 323-224-3900
- Website
- responsegenetics.com
About Response Genetics Inc
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.